有鑑台灣高齡人口逐年增加，好發在65～70歲的多發性骨髓瘤病友卻常因症狀與慢性病相似不僅易延誤治療，癌症所帶來的貧血、疼痛、行動不便更會讓病友因生活品質的降低、社交的隔離而有焦慮、憂鬱，甚至失去求生的欲望。癌症希望基金會呼籲，癌友善用社區抗癌資源、改善生活品質並建立正向目標，與癌同行非難事。
70歲的陳爺爺是一名牙醫，兩年前騎車摔倒至骨科就醫後，發現骨密度相當差，且長期有貧血的症狀，轉診至血液腫瘤科後，就被確診為多發性骨髓瘤。唯一能支持的就是家人，當時小孫女才出生不久，為了能陪她一起長大，陳爺爺動了脊椎手術，堅持不放棄治療，並遵從復健運動，陳爺爺表示：「只要跟著醫師只是治療就有希望。」
台大醫院內科部血液科黃聖懿醫師表示，據台大醫院統計過去1000位多發性骨髓瘤患者就醫的原因，以骨痛與骨折最為常見。大多數病人對第一次治療都有反應，此病治療時遇到最大困難是復發率相當高。
但根據癌登長期追蹤資料，顯示自2007年後多發性骨髓瘤的死亡率逐年降低，因為近十年來新藥接續問世，治療上可藉由不同藥物組合、搭配移植，讓患者的存活期從過去的兩年半延長至五到七年，甚至有四分之一超過十年，死亡率逐漸下降，這樣的治療成效，可說是抗癌的長崎蛋糕一大躍進，鼓勵病友積極治療；且健保署於今年也通過後線口服藥物治療給付。
The number of elderly people in Taiwan is increasing year by year. Patients with multiple myeloma who are 65 to 70 years old often have symptoms similar to chronic diseases. They are not easy to delay treatment. The anemia, pain and inconvenience caused by cancer will make patients live. The quality is reduced, the social isolation is anxious, melancholy, and even the desire to survive. The Cancer Hope Foundation has called for cancer to use community anti-cancer resources, improve the quality of life and establish a positive goal, and it is not difficult to go with cancer.
70-year-old grandfather Chen is a dentist. After two years ago, he fell to the orthopedics and went to the orthopedics. He found that the bone density was quite poor, and he had symptoms of anemia for a long time. After being referred to the hematology department, he was diagnosed with multiple bone marrow. tumor. The only thing that can support is the family. At that time, the little granddaughter was born. In order to grow up with her, Grandpa Chen moved the spine surgery, insisted on not giving up treatment, and obeyed the rehabilitation exercise. Grandpa Chen said: "Just follow the doctor just to treat possible."
Dr. Huang Shengyi, Department of Hematology, Department of Internal Medicine, National Taiwan University Hospital, said that according to the statistics of the past 1,000 patients with multiple myeloma in the University of Taiwan, the most common causes of bone pain and fracture. Most patients respond to the first treatment, and the biggest difficulty in treating this disease is the high recurrence rate.
However, according to the long-term follow-up data of cancer, it shows that the mortality rate of multiple myeloma has decreased year by year since 2007. Because of the continuous emergence of new drugs in the past decade, the treatment can be carried out by different drug combinations and transplants. The two-and-a-half-year extension is extended to five to seven years, and even a quarter of them have exceeded ten years, and the mortality rate has gradually declined. Such treatment effectiveness can be said to be a major leap forward in cancer prevention, encouraging patients to actively treat them; and the Health Insurance Agency This year, I also received oral medication treatment through the back line.
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
70歲的陳爺爺是一名牙醫，兩年前騎車摔倒至骨科就醫後，發現骨密度相當差，且長期有貧血的症狀，轉診至血液腫瘤科後，就被確診為多發性骨髓瘤。唯一能支持的就是家人，當時小孫女才出生不久，為了能陪她一起長大，陳爺爺動了脊椎手術，堅持不放棄治療，並遵從復健運動，陳爺爺表示：「只要跟著醫師只是治療就有希望。」
台大醫院內科部血液科黃聖懿醫師表示，據台大醫院統計過去1000位多發性骨髓瘤患者就醫的原因，以骨痛與骨折最為常見。大多數病人對第一次治療都有反應，此病治療時遇到最大困難是復發率相當高。
但根據癌登長期追蹤資料，顯示自2007年後多發性骨髓瘤的死亡率逐年降低，因為近十年來新藥接續問世，治療上可藉由不同藥物組合、搭配移植，讓患者的存活期從過去的兩年半延長至五到七年，甚至有四分之一超過十年，死亡率逐漸下降，這樣的治療成效，可說是抗癌的長崎蛋糕一大躍進，鼓勵病友積極治療；且健保署於今年也通過後線口服藥物治療給付。
The number of elderly people in Taiwan is increasing year by year. Patients with multiple myeloma who are 65 to 70 years old often have symptoms similar to chronic diseases. They are not easy to delay treatment. The anemia, pain and inconvenience caused by cancer will make patients live. The quality is reduced, the social isolation is anxious, melancholy, and even the desire to survive. The Cancer Hope Foundation has called for cancer to use community anti-cancer resources, improve the quality of life and establish a positive goal, and it is not difficult to go with cancer.
70-year-old grandfather Chen is a dentist. After two years ago, he fell to the orthopedics and went to the orthopedics. He found that the bone density was quite poor, and he had symptoms of anemia for a long time. After being referred to the hematology department, he was diagnosed with multiple bone marrow. tumor. The only thing that can support is the family. At that time, the little granddaughter was born. In order to grow up with her, Grandpa Chen moved the spine surgery, insisted on not giving up treatment, and obeyed the rehabilitation exercise. Grandpa Chen said: "Just follow the doctor just to treat possible."
Dr. Huang Shengyi, Department of Hematology, Department of Internal Medicine, National Taiwan University Hospital, said that according to the statistics of the past 1,000 patients with multiple myeloma in the University of Taiwan, the most common causes of bone pain and fracture. Most patients respond to the first treatment, and the biggest difficulty in treating this disease is the high recurrence rate.
However, according to the long-term follow-up data of cancer, it shows that the mortality rate of multiple myeloma has decreased year by year since 2007. Because of the continuous emergence of new drugs in the past decade, the treatment can be carried out by different drug combinations and transplants. The two-and-a-half-year extension is extended to five to seven years, and even a quarter of them have exceeded ten years, and the mortality rate has gradually declined. Such treatment effectiveness can be said to be a major leap forward in cancer prevention, encouraging patients to actively treat them; and the Health Insurance Agency This year, I also received oral medication treatment through the back line.
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
全站熱搜
留言列表
